Literature DB >> 16453338

Mechanisms of the interaction between two ADAMTS13 gene mutations leading to severe deficiency of enzymatic activity.

Flora Peyvandi1, Silvia Lavoretano, Roberta Palla, Carla Valsecchi, Giuliana Merati, Raimondo De Cristofaro, Edoardo Rossi, Pier Mannuccio Mannucci.   

Abstract

The inherited deficiency of the von Willebrand factor-cleaving protease ADAMTS13 is associated with rare forms of thrombotic thrombocytopenic purpura (TTP). We investigated a woman with a family history of chronic recurrent TTP and undetectable plasma levels of ADAMTS13 activity. Genetic analysis revealed two missense mutations in the heterozygous state: p.Val88Met substitution in the metalloprotease domain and p.Gly1239Val substitution in the first CUB domain of ADAMTS13. To explore the mechanism of ADAMTS13 deficiency in this patient, the wild type (WT; ADAMT13(WT)) and each mutant construct (ADAMTS13(Val88Met), ADAMTS13(Gly1239Val)) were transiently expressed in HEK 293 and COS-7 cells. To recapitulate the compound heterozygous state of the patient, both mutant ADAMTS13 proteins were also expressed together. The p.Val88Met mutation led to a defect of secretion of the protease associated with a reduction of enzymatic activity, the p.Gly1239Val mutation led to a secretion defect causing intracellular accumulation of the protease. The mechanistic effects of the mutations were further explored by means of differential immunofluorescence, that demonstrated an homogeneous distribution of ADAMTS13(WT) in the Cis-Golgi and endoplasmic reticulum (ER) compartments, a reduction of ADAMTS13(Val88Met) in both compartments, while ADAMTS13(Gly1239Val) failed to reach the Cis-Golgi compartment and remained in the ER. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16453338     DOI: 10.1002/humu.20267

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  8 in total

Review 1.  Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura.

Authors:  Minola Manea; Diana Karpman
Journal:  Pediatr Nephrol       Date:  2008-09-20       Impact factor: 3.714

2.  Two novel heterozygote missense mutations of the ADAMTS13 gene in a child with recurrent thrombotic thrombocytopenic purpura.

Authors:  Raffaella Rossio; Barbara Ferrari; Andrea Cairo; Ilaria Mancini; Giovanni Pisapia; Giulia Palazzo; Flora Peyvandi
Journal:  Blood Transfus       Date:  2012-09-12       Impact factor: 3.443

Review 3.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

Review 4.  Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children.

Authors:  Chantal Loirat; Jean-Pierre Girma; Céline Desconclois; Paul Coppo; Agnès Veyradier
Journal:  Pediatr Nephrol       Date:  2008-06-24       Impact factor: 3.714

5.  The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13 in a family with inherited thrombotic thrombocytopenic purpura.

Authors:  Roberta Palla; Silvia Lavoretano; Rossana Lombardi; Isabella Garagiola; Mehran Karimi; Abdolreza Afrasiabi; Mani Ramzi; Raimondo De Cristofaro; Flora Peyvandi
Journal:  Haematologica       Date:  2008-12-30       Impact factor: 9.941

6.  Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura.

Authors:  Luca A Lotta; Haifeng M Wu; Ian J Mackie; Marina Noris; Agnes Veyradier; Marie A Scully; Giuseppe Remuzzi; Paul Coppo; Ri Liesner; Roberta Donadelli; Chantal Loirat; Richard A Gibbs; April Horne; Shangbin Yang; Isabella Garagiola; Khaled M Musallam; Flora Peyvandi
Journal:  Blood       Date:  2012-04-23       Impact factor: 22.113

7.  ADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura.

Authors:  Minola Manea; AnnCharlotte Kristoffersson; Han-Mou Tsai; Wenhua Zhou; Ingemar Winqvist; Göran Oldaeus; Rolf Billström; Peter Björk; Lars Holmberg; Diana Karpman
Journal:  Eur J Pediatr       Date:  2006-12-24       Impact factor: 3.183

8.  Next-Generation Sequencing and In Vitro Expression Study of ADAMTS13 Single Nucleotide Variants in Deep Vein Thrombosis.

Authors:  Maria Teresa Pagliari; Luca A Lotta; Hugoline G de Haan; Carla Valsecchi; Gloria Casoli; Silvia Pontiggia; Ida Martinelli; Serena M Passamonti; Frits R Rosendaal; Flora Peyvandi
Journal:  PLoS One       Date:  2016-11-01       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.